Clinical Trial Update: Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study completed evaluating the effect of BMS-791325 on the QTcF interval in healthy subjects; the trial was sponsored by Bristol-Myers Squibb in relatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-791325

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED